rundc3a Antibody

What is RUNDC3A and what role does it play in cellular function?

RUNDC3A (RUN Domain Containing 3A) is a protein known to play important roles in several cellular processes including cell proliferation, apoptosis, and differentiation. Research has demonstrated that dysregulation of RUNDC3A has been implicated in various diseases, particularly cancer . The protein appears to function in signaling pathways that regulate cell growth and survival, making it a significant target for oncology research. Understanding RUNDC3A's normal cellular functions provides the foundation for investigating its roles in pathological conditions.

What validated applications are available for RUNDC3A antibodies in laboratory research?

RUNDC3A antibodies, such as the RUNDC3A Polyclonal Antibody (PACO36118), have been validated for multiple laboratory applications including:

• Western blot (WB) with recommended dilutions of 1:500-1:2000

• Immunohistochemistry (IHC) with recommended dilutions of 1:20-1:200

• Enzyme-linked immunosorbent assay (ELISA) with recommended dilutions of 1:2000-1:10000

These applications enable researchers to detect and quantify RUNDC3A protein expression in various experimental contexts, from cell lysates to tissue samples. The specificity of these antibodies for human samples makes them particularly valuable for translational research.

What is the relationship between RUNDC3A and RUNDC3A-AS1 in research contexts?

While RUNDC3A is a protein-coding gene, RUNDC3A-AS1 is a long non-coding RNA (lncRNA) that is antisense to the RUNDC3A gene. Research has revealed that RUNDC3A-AS1 is highly expressed in thyroid cancer cells and tissues . The relationship between RUNDC3A protein and RUNDC3A-AS1 lncRNA represents an important area of investigation, as both appear to influence cell proliferation and apoptosis, albeit through potentially different mechanisms. Understanding this relationship may provide insights into gene regulation and disease progression.

What are the optimal protocols for using RUNDC3A antibodies in Western blot applications?

For optimal Western blot results with RUNDC3A antibody:

• Sample preparation: Use appropriate lysis buffers containing protease inhibitors to extract total protein from cells or tissues

• Protein loading: Load 20-50 μg of total protein per lane

• Antibody dilution: Use RUNDC3A antibody at a 1:500-1:2000 dilution in 5% BSA or non-fat milk

• Secondary antibody: Apply goat polyclonal to rabbit IgG at 1/10000 dilution

• Detection: The predicted band size for RUNDC3A is approximately 50, 46, and 42 kDa, with observed band size of 50 kDa in MCF-7 whole cell lysate

This protocol has been validated with human samples and produces reliable results for detecting RUNDC3A protein expression.

How should researchers design knockdown experiments to study RUNDC3A or RUNDC3A-AS1 function?

When designing knockdown experiments for RUNDC3A-AS1:

• Validate multiple siRNA or shRNA constructs to ensure specificity and efficiency

• Use appropriate negative controls (scrambled sequences)

• Confirm knockdown efficiency via RT-qPCR (for RUNDC3A-AS1 lncRNA)

• Select cell lines with high endogenous expression (e.g., TPC-1 and IHH4 cells for RUNDC3A-AS1)

• Include functional assays to assess biological consequences:

  • Cell proliferation: EdU, CCK-8, and MTT assays

  • Cell apoptosis: Flow cytometry

  • Cell migration and invasion: Transwell chamber and wound scratch assays

Similar approaches can be adapted for RUNDC3A protein studies, with protein knockdown verification by Western blot using validated RUNDC3A antibodies.

What controls should be included when using RUNDC3A antibodies in immunohistochemistry?

For rigorous IHC experiments with RUNDC3A antibodies:

• Positive tissue controls: Include tissues known to express RUNDC3A

• Negative tissue controls: Include tissues known not to express RUNDC3A

• Antibody controls:

  • Primary antibody omission control

  • Isotype control (rabbit IgG at matching concentration)

  • Blocking peptide control (pre-incubation with immunizing peptide)

• Dilution optimization: Test the recommended range (1:20-1:200) to determine optimal signal-to-noise ratio

• Antigen retrieval method validation: Compare heat-induced vs. enzymatic methods

These controls ensure specificity of staining and allow confident interpretation of RUNDC3A expression patterns in tissue samples.

How can researchers investigate the regulatory relationship between RUNDC3A-AS1 and its target microRNAs?

To investigate RUNDC3A-AS1's regulation of microRNAs:

• Bioinformatic prediction: Identify potential microRNA binding sites on RUNDC3A-AS1 using algorithms like miRanda, TargetScan, or RNAhybrid

• Luciferase reporter assays: Generate wild-type and mutant RUNDC3A-AS1 luciferase reporter constructs with altered microRNA binding sites

• RNA immunoprecipitation (RIP): Assess the physical interaction between RUNDC3A-AS1 and microRNAs within the RNA-induced silencing complex

• Rescue experiments: Demonstrate that microRNA mimics/inhibitors can rescue or replicate the phenotypes observed with RUNDC3A-AS1 manipulation

For example, research has confirmed that RUNDC3A-AS1 targets miR-151b in thyroid cancer and serves as an inhibitor of miR-182-5p in tumor tissues and cell lines .

What methodological approaches can determine if RUNDC3A-AS1 acts through different pathways in different cancer types?

To investigate cancer-specific pathways:

• Comparative transcriptomics: Perform RNA-seq after RUNDC3A-AS1 knockdown in multiple cancer cell lines

• Pathway enrichment analysis: Identify differentially affected signaling pathways across cancer types

• Target validation: Confirm key downstream targets like:

  • SNRPB in thyroid cancer

  • ADAM9 in metastatic thyroid cancer

• In vivo models: Develop cancer-specific xenograft models to validate in vitro findings

• Patient sample analysis: Compare RUNDC3A-AS1 expression and pathway activation across cancer types using clinical specimens

Research has demonstrated that RUNDC3A-AS1 regulates different molecular targets in various contexts, such as miR-151b/SNRPB and miR-182-5p/ADAM9 axes in thyroid cancer .

How can in vivo models be optimized to study RUNDC3A-AS1's role in cancer metastasis?

For optimal in vivo metastasis studies:

• Cell line selection: Choose highly metastatic cell lines (e.g., K1 thyroid cancer cells) with stable RUNDC3A-AS1 knockdown

• Injection route optimization:

  • Tail vein injection for lung metastasis models

  • Orthotopic injection for primary tumor formation and spontaneous metastasis

• Monitoring techniques:

  • Bioluminescence imaging for real-time tracking

  • Weekly imaging to document metastatic progression

• Endpoint analyses:

  • Histopathological examination (H&E staining)

  • Fibrosis assessment (Masson staining)

  • RT-qPCR to confirm altered expression of RUNDC3A-AS1 and its downstream targets

This approach has successfully demonstrated that knockdown of RUNDC3A-AS1 significantly decreases lung metastatic nodules and pulmonary fibrosis in mouse models of thyroid cancer .

What signaling pathways are affected by RUNDC3A-AS1 in cancer progression?

RUNDC3A-AS1 influences several key signaling pathways in cancer:

• EMT signaling: RUNDC3A-AS1 knockdown increases E-cadherin expression while decreasing N-cadherin, Snail, and Slug in thyroid cancer cells

• Matrix metalloproteinase pathways: RUNDC3A-AS1 regulates expression of MMP-2 and MMP-9, critical mediators of invasion and metastasis

• Inflammatory signaling: RUNDC3A-AS1 affects Cox-2 expression, linking to inflammatory processes in cancer

• miRNA-mediated pathways:

  • RUNDC3A-AS1/miR-151b/SNRPB axis affects cell proliferation and apoptosis

  • RUNDC3A-AS1/miR-182-5p/ADAM9 axis promotes metastasis

These findings indicate that RUNDC3A-AS1 acts through multiple mechanisms to promote cancer progression, affecting both proliferation and metastatic potential.

How does subcellular localization of RUNDC3A-AS1 inform its mechanism of action?

The subcellular localization of RUNDC3A-AS1 provides important insights into its function:

• Subcellular fractionation assays reveal that RUNDC3A-AS1 is primarily located in the cytoplasm of thyroid cancer cells

• This cytoplasmic localization suggests post-transcriptional regulatory functions rather than direct transcriptional regulation

• Cytoplasmic lncRNAs often function as:

  • microRNA sponges (competing endogenous RNAs)

  • Protein-binding partners affecting protein stability or localization

  • Translational regulators

The confirmed cytoplasmic localization of RUNDC3A-AS1 aligns with its demonstrated function as a microRNA sponge for miR-151b and miR-182-5p, explaining its molecular mechanism in cancer progression .

What techniques can be used to identify novel protein interactions with RUNDC3A?

To discover novel RUNDC3A protein interactions:

• Immunoprecipitation (IP) followed by mass spectrometry:

  • Use validated RUNDC3A antibodies for pull-down experiments

  • Identify co-precipitated proteins by mass spectrometry analysis

  • Confirm interactions with reciprocal IP experiments

• Proximity labeling techniques:

  • BioID or APEX2 fusion proteins to biotinylate proximal proteins

  • Identify biotinylated proteins as potential interactors

• Yeast two-hybrid screening:

  • Use RUNDC3A as bait to screen cDNA libraries

  • Validate interactions with complementary approaches

• Co-localization studies:

  • Immunofluorescence using RUNDC3A antibody and antibodies against candidate interactors

  • Super-resolution microscopy for detailed co-localization analysis

• Protein-fragment complementation assays:

  • Split reporter systems to confirm direct protein-protein interactions in live cells

These approaches can reveal novel signaling partners and functional complexes involving RUNDC3A protein.

How can RUNDC3A-AS1 expression data be effectively analyzed in clinical thyroid cancer samples?

For robust clinical sample analysis:

• Sample collection and processing:

  • Collect paired tumor and peritoneal tissues from thyroid cancer patients

  • Ensure proper preservation for RNA integrity

  • Record comprehensive clinical data (age, gender, tumor stage, etc.)

• Expression analysis:

  • Use RT-qPCR for RUNDC3A-AS1 quantification

  • Include appropriate reference genes for normalization

  • Analyze in conjunction with miR-151b, miR-182-5p, SNRPB, and ADAM9 expression

• Clinical correlation:

  • Stratify patients by RUNDC3A-AS1 expression levels

  • Correlate with clinical parameters and outcomes

  • Perform multivariate analysis to identify independent prognostic factors

This approach has been validated in clinical studies involving 30 thyroid cancer patients (13 males and 17 females) where RUNDC3A-AS1 was found to be upregulated in tumor tissues compared to matched normal tissues .

What methodologies can determine if RUNDC3A antibodies are suitable for diagnostic applications?

To evaluate diagnostic potential:

• Antibody validation:

  • Determine specificity across multiple tissue types

  • Assess sensitivity in detecting varying expression levels

  • Confirm reproducibility across different laboratories

• Clinical sample testing:

  • Test on tissue microarrays containing multiple cancer and normal samples

  • Establish standardized staining protocols and scoring systems

  • Correlate staining with tumor grade, stage, and patient outcomes

• Comparative analysis:

  • Compare RUNDC3A antibody performance against established diagnostic markers

  • Assess added diagnostic value in multimarker panels

  • Determine positive and negative predictive values

• Validation cohorts:

  • Test on independent patient cohorts

  • Perform blinded evaluations by multiple pathologists

  • Calculate inter-observer and intra-observer agreement

These rigorous validation steps are essential before RUNDC3A antibodies can be considered for diagnostic applications.

How can machine learning approaches be integrated with RUNDC3A antibody research for improved target specificity?

Machine learning integration strategies:

• Antibody complementarity determining region (CDR) design:

  • Use high-capacity neural networks to model antibody-antigen interactions

  • Train models on existing affinity data from phage display experiments

  • Generate novel CDR sequences with improved RUNDC3A specificity

• Epitope prediction and optimization:

  • Employ machine learning algorithms to identify optimal epitopes on RUNDC3A

  • Design antibodies targeting these specific regions

  • Validate computational predictions with experimental testing

• Affinity maturation:

  • Combine traditional randomized affinity maturation with machine learning

  • Use models to predict which mutations will improve binding affinity

  • Test a smaller, more targeted library of candidate antibodies

• Cross-reactivity prediction:

  • Train models to predict potential cross-reactivity with similar proteins

  • Design antibodies with improved specificity for RUNDC3A

This approach has shown promise in designing antibody CDRs with target affinities without requiring knowledge of the antigen's molecular structure .

How can researchers troubleshoot non-specific binding when using RUNDC3A antibodies?

To address non-specific binding issues:

• Optimize blocking conditions:

  • Test different blocking agents (BSA, non-fat milk, normal serum)

  • Increase blocking time or concentration

  • Add 0.1-0.3% Tween-20 to reduce hydrophobic interactions

• Antibody dilution optimization:

  • Test a range of dilutions beyond the recommended 1:500-1:2000 for WB

  • Perform titration experiments to find optimal signal-to-noise ratio

• Washing optimization:

  • Increase number or duration of wash steps

  • Use higher concentrations of detergent in wash buffers

• Cross-adsorption:

  • Pre-incubate antibody with tissues/lysates known to cause cross-reactivity

  • Use commercially available cross-adsorbed secondary antibodies

• Alternative antibody selection:

  • Test monoclonal alternatives if polyclonal shows high background

  • Consider antibodies targeting different epitopes of RUNDC3A

These systematic approaches can significantly reduce non-specific binding and improve experimental results.

What factors should be considered when optimizing RUNDC3A-AS1 knockdown efficiency?

For optimal RUNDC3A-AS1 knockdown:

• siRNA/shRNA design considerations:

  • Target regions with high accessibility and low secondary structure

  • Avoid regions with homology to other transcripts

  • Design multiple constructs targeting different regions

  • Consider using pooled siRNAs to increase efficiency

• Transfection optimization:

  • Compare different transfection reagents (lipid-based, electroporation)

  • Optimize cell density at transfection time

  • Adjust reagent-to-nucleic acid ratios

  • Consider cell type-specific protocols

• Knockdown verification:

  • Measure knockdown efficiency by RT-qPCR at multiple time points

  • Compare expression to both untreated and negative control treated cells

  • Aim for >70% knockdown efficiency for functional studies

• Stable vs. transient knockdown:

  • For long-term studies, establish stable knockdown cell lines

  • Validate knockdown stability over multiple passages

These optimizations ensure reliable and reproducible RUNDC3A-AS1 knockdown for downstream functional studies.

How can researchers address contradictory findings regarding RUNDC3A-AS1 function across different experimental systems?

To resolve contradictory findings:

• Experimental system analysis:

  • Compare cell line characteristics (origin, mutations, culture conditions)

  • Assess baseline expression levels of RUNDC3A-AS1 and related factors

  • Consider in vitro vs. in vivo differences

• Methodological standardization:

  • Use consistent knockdown/overexpression approaches

  • Standardize functional assay protocols

  • Apply uniform data analysis methods

• Pathway context evaluation:

  • Assess status of related pathways in different systems

  • Profile microRNA expression patterns across cell types

  • Investigate potential compensatory mechanisms

• Independent validation:

  • Replicate key experiments in multiple laboratories

  • Use alternative approaches to confirm findings

  • Consider patient-derived models for clinical relevance

• Meta-analysis:

  • Systematically review and integrate findings across studies

  • Identify patterns explaining apparent contradictions

  • Develop unified models accounting for context-specific effects

This structured approach can help resolve contradictions and develop a more comprehensive understanding of RUNDC3A-AS1 function.